Metformin for PCOS

Metformin is a biguanide the FDA approved only as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes. Every use in PCOS is off-label. That is legal and routine, but it means the label carries no PCOS dose, no PCOS endpoints and no PCOS-specific safety section. Your clinician is reasoning across from diabetes data and from PCOS trials that sit outside the approval. Guideline text matters more here than the package insert.

The mechanism is why anyone bothered. Women with PCOS show marked insulin resistance independent of obesity, driven by a post-receptor signaling defect, and insulin functions as a co-gonadotropin that modulates ovarian steroidogenesis. High circulating insulin therefore feeds ovarian androgen production. Reduce the insulin signal and you take pressure off that loop. Metformin therefore moves metabolic and cycle measures further than it moves hair growth. A PCOS diagnosis is considered enduring or lifelong, so nothing here is a one-time fix.

The largest synthesis is a Cochrane review of 48 studies in 4,451 women. Against placebo, metformin improved ovulation with an odds ratio of 2.55 (95% CI 1.81 to 3.59), rated moderate quality evidence, and menstrual frequency with an odds ratio of 1.72 (95% CI 1.14 to 2.61), rated low quality. Clinical pregnancy improved with an odds ratio of 1.93 (95% CI 1.42 to 2.64), also graded moderate. Live birth came in at 1.59 with a confidence interval of 1.00 to 2.51, graded low, which just touches the line of no effect.

Read those as shifts in odds. They are not promises.

An odds ratio of 2.55 for ovulation still leaves a large share of women ovulating no more often than before, and a trial average tells you nothing about which group you land in. The same review found gastrointestinal adverse effects with an odds ratio of 4.76 (95% CI 3.06 to 7.41), rated moderate quality, which is the same grade the ovulation figure carries. Live birth is the outcome graded low, and that is the one to hold onto if pregnancy is your reason for considering it. Those trials ran over months, so judge your own response across several cycles.

The 2023 International Evidence-Based Guideline is the reference most US clinicians work from, and it is explicit that combined oral contraceptive pills are the first line pharmacological treatment for menstrual irregularity and hyperandrogenism, while metformin is recommended primarily for metabolic features. That ordering matters. If your headline complaint is an unpredictable cycle, acne or unwanted hair growth, metformin is usually not the first drug the guideline reaches for.

Its own metformin recommendations carry low certainty grades. Metformin alone should be considered in adults with PCOS and a BMI at or above 25 for anthropometric and metabolic outcomes including insulin resistance, glucose and lipid profiles, and where the pill is contraindicated, not accepted or not tolerated, metformin may be considered for irregular menstrual cycles, while hirsutism may need other interventions. Against supplements, metformin is favored over inositol for hirsutism and central adiposity, noting more gastrointestinal side effects.

The single most useful expectation-setting line is a practice point: women should be informed that metformin and active lifestyle intervention have similar efficacy. The same document recommends lifestyle intervention for everyone with PCOS. Read together, metformin is an addition to that work rather than a replacement for it, and a service that hands you a tablet and nothing else has given you roughly half of what the guideline describes.

Letrozole should be the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS and no other infertility factors, and it carries the guideline's highest strength and evidence ratings. Below it, clomiphene citrate could be used in preference to metformin. The Cochrane numbers are blunt about that gap: in obese women the live birth odds ratio was 0.30 (95% CI 0.17 to 0.52) favoring clomiphene over metformin.

So metformin comes third in that order. It is not the fertility drug.

It is not off the table. The guideline allows that metformin could be used alone in anovulatory infertility with no other infertility factors to improve clinical pregnancy and live birth rates, while informing women that there are more effective ovulation agents, and notes that healthcare and resource burden including monitoring, travel and costs are lower with metformin. Separately, metformin in pregnancy has not been shown to prevent gestational diabetes, late miscarriage, hypertension in pregnancy, pre-eclampsia or macrosomia.

The usual starting dose of immediate-release metformin is 500 mg twice a day or 850 mg once a day with meals, raised in 500 mg weekly steps to 2000 mg daily in divided doses, while extended release starts at 500 mg once daily with the evening meal and rises in 500 mg weekly steps to a maximum of 2000 mg once daily. For PCOS specifically the guideline advises starting at a low dose with 500 mg increments one to two weekly, with a suggested maximum of 2.5 g daily in adults and 2 g in adolescents.

The extended-release tolerability story is oversold, and it is worth knowing why. Across the label's separate placebo-controlled programs, diarrhea was reported by 53.2% on immediate release against 9.6% on extended release, and it led to discontinuation in 6% against 0.6%. Those figures come from two separate trial programs, never a head-to-head. When nine randomized trials in 2,609 adults compared equal daily doses directly, extended release only reduced dyspepsia (RR 0.58, 95% CI 0.34 to 0.98), with other key gastrointestinal symptoms occurring at similar rates. Both things can be true: the guideline still says extended-release preparations may minimize side effects and improve adherence, and once-daily dosing is easier to stick with than three tablets. Just do not expect the gap the label tables suggest. Gastrointestinal effects are generally dose dependent and self-limiting, so slow titration and taking each dose with food are the levers that actually matter.

In the label's monotherapy study, diarrhea occurred in 53.2% against 11.7% on placebo, nausea or vomiting in 25.5% against 8.3%, and flatulence in 12.1% against 5.5%. Metformin also carries a boxed warning: postmarketing cases of metformin-associated lactic acidosis have resulted in death, with risk factors including renal impairment, age 65 or older, contrast imaging, excessive alcohol intake and hepatic impairment. It is contraindicated in severe renal impairment, defined as an eGFR below 30 mL/min/1.73 m2.

The slow-burn issue is vitamin B12, and it is the one most often skipped. In the Diabetes Prevention Program Outcomes Study, low B12 at or below 203 pg/mL occurred in 4.3% on metformin against 2.3% on placebo at five years, combined low and borderline-low B12 in 19.1% against 9.5%, and each year of metformin use carried an odds ratio of 1.13 (95% CI 1.06 to 1.20) for deficiency. The PCOS guideline agrees that monitoring for low vitamin B12 should be considered during ongoing use.

Metformin is prescription-only in the US, and PCOS is a diagnosis of exclusion that no intake form can make on its own. The guideline sets real requirements around the prescription: glycaemic status should be assessed at diagnosis in all adults and adolescents with PCOS and reassessed every one to three years, and regardless of age and BMI, women with PCOS carry increased risk of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes. A platform that prescribes without touching any of that is skipping the part that justifies the script.

A workable intake covers your cycle history, whether thyroid disease and elevated prolactin have already been excluded, current or planned pregnancy, alcohol intake and kidney function. Kidney function is not optional given the eGFR contraindication. None of this is medical advice, and whether metformin suits you is a call for a licensed clinician with your labs in front of them. If your interest is mainly the weight side of metformin, that evidence is covered separately on our metformin for weight loss page.

The combination of the combined oral contraceptive pill and metformin could be considered to offer little additional clinical benefit over either alone in adults with PCOS and a BMI at or below 30. Above that line, the combination may be most beneficial in high metabolic risk groups including a BMI over 30, diabetes risk factors, impaired glucose tolerance or high-risk ethnic groups. So stacking the two is a metabolic-risk decision with a threshold attached. It is not a default upgrade.

On supplements, metformin should be considered over inositol for hirsutism and central adiposity, noting that metformin has more gastrointestinal side effects than inositol, and specific types, doses or combinations of inositol cannot currently be recommended due to a lack of quality evidence. Lifestyle change sits underneath all of it. Since metformin and active lifestyle intervention were judged similarly effective, dropping the lifestyle half and keeping only the tablet gives away a large part of the plan.

Metformin is among the cheapest prescriptions in American pharmacy, and the public benchmark shows how cheap. NADAC is the federal survey of what pharmacies pay to acquire a drug, and it lists metformin 500 mg immediate release at $0.01419 per tablet and metformin ER 500 mg at $0.02879 per tablet in the file published on 2 September 2026. At 1,000 mg a day that is under a dollar a month of drug at acquisition cost, and roughly $2.60 a month for 1,500 mg of the extended-release form.

That is not what you will pay.

Acquisition cost excludes the dispensing fee, the pharmacy margin, and whatever a telehealth service charges for the consult and follow-up. Cash prices move by pharmacy and by month, so check yours before assuming anything. The directional read is the useful part: the medicine itself is close to free, and almost everything on your invoice buys access to a prescriber and the lab work that should come with the prescription.

Judge a service on what it does around the prescription rather than how fast it issues one. Ask whether kidney function is checked before the first script, since severe renal impairment is a contraindication. Ask how glycemic status will be assessed and on what schedule it gets rechecked, because the guideline sets a one to three year cadence. Ask who reads your results, and how you reach a human in the first two weeks when the gut effects are at their worst.

Ask about the exit as well. This page is information rather than medical advice, and the prescribing call belongs to your clinician. If nothing has shifted after a fair trial, a good clinician revisits the plan instead of raising the dose indefinitely. Given that the guideline puts the pill first for cycles and hyperandrogenism and letrozole first for ovulation induction, a service that only stocks metformin has a narrow toolkit for a condition with several levers.